학술논문

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies
Document Type
article
Source
Journal of Antimicrobial Chemotherapy. 70(7)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Clinical Sciences
Infectious Diseases
HIV/AIDS
Antimicrobial Resistance
6.1 Pharmaceuticals
Evaluation of treatments and therapeutic interventions
Infection
Anti-HIV Agents
Disease Transmission
Infectious
Drug Resistance
Viral
Female
France
Genotype
Genotyping Techniques
HIV Infections
HIV-1
Homosexuality
Male
Humans
Male
Mutation
Missense
Prevalence
resistance-associated mutations
primary HIV infection
French ANRS CO 6 PRIMO Cohort
the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups
French ANRS CO 6 PRIMO Cohort the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups
Microbiology
Pharmacology and Pharmaceutical Sciences
Clinical sciences
Pharmacology and pharmaceutical sciences
Language
Abstract
BackgroundOur study describes the prevalence of transmitted drug resistance (TDR) among 1318 French patients diagnosed at the time of primary HIV-1 infection (PHI) in 2007-12.MethodsHIV-1 resistance-associated mutations (RAMs) were characterized using both the 2009 WHO list of mutations and the French ANRS algorithm. A genotypic susceptibility score was estimated for each first-line recommended ART combination.ResultsPatients were mainly MSM (72.6%). Non-B variants were identified in 33.7% of patients. The proportion of TDR was estimated as 11.7% (95% CI 10.0-13.5). The prevalences of PI-, NRTI-, first-generation NNRTI and etravirine/rilpivirine-associated RAMs were 2.5%, 5.2%, 3.9% and 3.2%, respectively. Single, dual and triple class resistance was found in 9.6%, 1.0% and 1.1% of cases, respectively. Additionally, 5/331 strains isolated in 2010-12 had integrase inhibitor (II)-related RAMs (isolated E157Q mutation in all cases). TDR was more common among MSM than in other groups (12.9% versus 8.6%, P = 0.034), and in case of B versus non-B subtype infections (13.6% versus 7.9%, P = 0.002). The proportions of fully active combinations were ≥99.2%, ≥97.3% and ≥95.3% in cases of PI-, II- and NNRTI-based regimens, respectively. In 2010-12, the proportion of fully active efavirenz-based ART was lower in cases of subtype B versus non-B infection (P = 0.021).ConclusionsCompared with our previous studies, the proportion of NRTI- and first-generation NNRTI-related TDR has continued to decline in French seroconverters. However, subtype B-infected MSM could drive the spread of resistant HIV strains. Finally, we suggest preferring PI- or II- to NNRTI-based combinations to treat PHI patients.